Skip to main content

Former Health Canada Inspector Dr. Sherry Boodram Joins Nextleaf Solutions Board Of Directors

Nextleaf Solutions, a leading cannabis extraction technology company, has announced today that it has added Dr. Sherry Boodram, former Senior Regulatory Compliance Officer with Health Canada, to its Board of Directors, effective immediately.

Dr. Sherry Boodram worked for the Canadian federal government for several years and was responsible for licensing application reviews and on-site facility inspections of Canadian cannabis industry facilities.

Dr. Boodram also provided field level input during the drafting of the current Canadian cannabis regulations.

“Being a company with values I can stand behind, I’m very excited to serve alongside Nextleaf’s existing Board members and with their talented executive team,” stated Dr. Sherry Boodram. “Moreover, I look forward to maximizing the unique knowledge and experience I gained while at Health Canada’s Medical Cannabis Program, and in the cannabis industry as a whole, to provide expertise in support of Nextleaf’s ongoing commitment to regulatory compliance, good governance, and long-term growth as a leader in cannabis extraction technology.”

Dr. Boodram holds a Ph.D. in Chemistry from York University, a B.Sc. (Hon) from the University of Toronto, and a Graduate Certificate with Honours in Pharmaceutical Regulatory Affairs and Quality Operations from Seneca College. Dr. Boodram is also a member of the Canadian Association of Professionals in Regulatory Affairs (CAPRA).

Currently, Dr. Boodram is the co-founder and CEO of CannDelta Inc. (“CannDelta”) – a regulatory and scientific cannabis consulting company based out of Toronto, Canada – where she provides regulatory expertise and develops strategies to ensure regulatory compliance within Canada’s existing legal cannabis framework.

“The serious regulatory infractions by several large Canadian licensed cannabis producers, along with an expanded scope of cannabis products through legalization 2.0, reinforces the critical role that compliance oversight plays in building a cannabis company all stakeholders can be proud of,” stated Paul Pedersen, co-founder and CEO of Nextleaf Solutions. “Sherry is amongst the most credible and qualified cannabis regulatory experts in Canada, and we believe her background, insights, and industry experience will add tremendous value to our Board.”

About Nextleaf Solutions

Nextleaf Solutions Ltd. (“OILS”) is developing disruptive intellectual property for industrial-scale extraction, purification, and formulation of cannabinoids. OILS owns a portfolio of eight (8) issued and 35 pending patents pertaining to the production of high-purity, cannabinoid-rich distillate, the key ingredient used in the manufacturing of standardized THC and CBD infused products. Once cannabis concentrates and edibles become legal across Canada, OILS plans to commercialize its intellectual property portfolio through IP licensing, B2B processing services, and the supply of THC and CBD oils and concentrates to qualified Canadian and international partners.

Nextleaf Solutions trades as OILS on the Canadian Securities Exchange (CSE: OILS), OILFF on the OTCQB Market in the United States (OTCQB: OILFF) and L0MA on the Frankfurt Stock Exchange (FSE: L0MA).

For more information visit www.nextleafsolutions.com or follow OILS across social media platforms: Twitter, LinkedIn, Facebook, and Instagram.

Would A Successful Brexit Boost The Chances Of British Cannabis Legalization?

It is no secret that the British are in a bit of a constitutional pickle at the moment. How far the country will align itself with the US and outside of the EU is still in play, two weeks out from Halloween. 

One of the stranger vibes in the air, especially after Boris Johnson hired two cannabis reform advocates into his office of late, is the idea that chucking the relationship with the EU and recreational cannabis reform might be linked, if not a good clarion call. 

After all, Aron Banks is no stranger to the CBD call either.

Are people on the British side of the industry seriously advocating Brexit as a way to push forward recreational cannabis reform in the UK? The answer, shockingly, appears to be yes.

Burn It All Down, Baby

For those at the pointed end of the cannabis discussion (namely patients), the debate about how money laundering laws are enforced to target cannabis-themed investments or not within the UK is currently a bit of a cruel joke. For anyone invested or working in the cannabis industry, the continued stutters and starts of the British market is not part of an academic discussion. 

Also, the snail’s pace of British cannabis reform has continued to prove to be too much for just about everyone. 

Who Can Blame The Brits For Wanting Their (Medical) Spice Cake And Eating It Too?

In this environment, it is tempting to just push recreational cannabis reform ideas under the larger ideas of burn, baby, burn which seems to now be in fashion in the geography of Number 10 (Downing Street and official residence of the British Prime Minister).

However, for those who think Brexit is a quick fix – think again.

Start with the fact that the UK is an island nation, and would be required to suddenly grow and source a huge amount of its own food and medicine. Also, the NHS would, as most believe now, simply not survive. Private (American-style) healthcare anyone?

While cannabis might in such circumstances come to be lauded as the wonder drug it is, like a new penicillin for example, does anyone think that bouncing the British economy around to do it under this kind of turbulence is really in the best interests of either patients or recreational consumers that would presumably be shell and wallet shocked?

Deregulation, in other words, and certainly of the kind that seems still to be in the room with a no-deal Brexit, might seem exciting, particularly to those frustrated with the hangover of the prohibition of the past.

However, such strategies are indeed a double-edged sword, both for (certainly) the British economy as well as Britain’s most vulnerable citizens who are cannabis users either “by choice” or through necessity.

How Might European Tax Credits Help Finance The Cannabis Industry?

For all of the hurdles that exist in the European market, there is one avenue that has, so far at least, remained remarkably unexplored. That is certainly the case on the financing end.

Yes, European family offices are conservative, and “equity” (at least as it is thought of in the North American sense) remains less interesting in the free for all of public markets among Europeans compared to their cross Atlantic peers.

However, for the right canna-entrepreneur, the most attractive thing about European financing so far has remained largely off the table. Namely tax credits, especially of the R&D and tech kind (although there are other kinds of credits on the table when crossing into related fields.)

Yes, there are rules about this kind of thing (and a lot of regulations). But as a vehicle for helping to offset the risk of evolving medical cannabis projects in particular, the pursuit of obtaining these tax credits has so far remained in its infancy.

It won’t for long. 

Where, Why and How Will This Impact Industry Growth?

For an industry that so far has financed its highest fliers via the public equity markets (and exotic financial instruments like reverse mergers), the European financing options now on the table are intriguing, if not much more attractively legit. 

Tax credits have already shown up of course. The largest firms from Canada are hip to this game. But increasingly so are the smaller players, and that is where tax credits and other financial instruments and structures here will start to play a bigger difference.

Writing off the construction of a GMP facility may not be entirely “experimental,” yet putting a new drug into it certainly could qualify. That’s especially true with any kind of qualifying research attached.

Right now, that is a siren’s song to a green industry that has frequently been short of cash.

Who Can Use This Kind Of Financing?

The best thing about tax credits is that they operate as a kind of insurance for investors looking for some way to offset the risk of investing in a new market. Cover the investment with a multi-year tax credit just in case? That is, for those who have a need for such vehicles, a no-lose proposition.

The only catch is that entrepreneurs need the right team (experts, including lawyers, and financiers are a must.) This is not something you do at home, or by yourself.

For the latest in Euro-financing strategies, be sure to attend the International Cannabis Business Conference 2020 in Europe in Barcelona, Berlin and Bern!

Demecan’s Successful Series A Financing Round Is A Major Milestone For Germany’s Domestic Cannabis Industry

Germany’s medical cannabis industry is increasing in size with every passing quarter. The profit potential for the nation’s emerging medical cannabis industry is significant considering that Germany is home to the largest economy in Europe and has more than twice the population of California.

For obvious reasons, Germany has been a very popular target for cannabis exports from other countries, including exports from Canada, Australia, Colombia, Portugal, and Uruguay.

Only one German-based company has permission to cultivate medical cannabis domestically. That company is Demecan. The Berlin startup recently completed a Series A financing round in which it raised €7 million to expand its ability to produce wholesale cannabis for the German medical cannabis market.

Demecan is expected to use the financing to ramp up cultivation, with an estimated output of at least 2,400 kilograms of dried cannabis flower over the course of the next four years.

Demecan may not be 100% German-owned (Canada’s Wayland Group owns 50% of Demecan), however, the recent financing is still very significant because it will help increase the amount of domestically cultivated cannabis in Germany in a way that results in wholesale revenues staying in Germany.

The German medical cannabis market possesses tremendous profit potential, yet it’s extremely important to keep in mind that revenues will be split up into various slices. As the slice for German-owned companies gets larger the slice for everyone else obviously becomes smaller.

Investors and entrepreneurs will have to adjust their strategies accordingly. That’s not to say that they should abandon efforts to gain market share in Germany altogether, because after all, the German medical cannabis industry is going to be huge.

However, it’s absolutely worth keeping a close eye on the situation to see how successful domestic production ultimately becomes in Germany. 

Domestic cultivation could prove to be more advantageous for various reasons compared to importing cannabis. One of the biggest reasons why is that domestic cannabis, and products derived from domestically cultivated cannabis, could prove to be considerably more popular among patients.

The demand for cannabis in Germany is going to continue to increase well into the foreseeable future. Recent data regarding reimbursements by statutory health insurers in German shows that for the April-June 2019 period sales reached roughly 29.5 million euros – a 20% increase over the previous quarter. That upward trend will continue.

Germany is currently the largest importer of cannabis on the planet. As domestically cultivated cannabis makes its way into the German medical cannabis market, it will have a big impact on the international cannabis industry.

International cannabis companies have been awarded licenses to cultivate medical cannabis within Germany’s borders, so it’s not as if German-based cannabis companies have a monopoly on cultivation.

However, Demecan’s successful series A financing round is still a huge milestone for the emerging German medical cannabis industry. Reliance on imports could reduce significantly in the coming years.

If Demecan puts their new funding to good use, and its domestic cannabis cultivation model succeeds in Germany, more funds will likely be on the way. That could have a butterfly effect on plans by international companies, with those companies scaling back their plans in Germany.

The domestic cultivation model could also be adopted elsewhere in Europe if Demecan is successful going forward, which would impact additional pursuits of international companies throughout the continent.

Of course, if Demecan fails to meet expectations due to a multitude of potential factors, that could result in other governments and investors opting to support industry models that are more reliant on imports.

A lack of supply is something that patients, lawmakers, and regulators in Germany want to avoid. That will also be true in other European countries as they ramp up their industries. 

The supply for Germany’s medical cannabis industry will obviously come from somewhere, the question that will ultimately be answered by the passing of time is what amount of that supply will originate from domestic sources versus what amount will be imported?

The success or failure of Demecan will have a big impact on what opportunities will be available in Germany in the coming years, and possibly in other countries. 

The Demecan situation will result in winners and losers. Which side of the equation will those winners and losers fall on? We will all have to wait and see. In the meantime, keep a close eye on the matter as it develops in order to make informed investment decisions in Germany and beyond.

Australia Launches Multi-Million Dollar Medical Cannabis Research Effort

The cannabis plant is one of the most useful plants on earth. It has the ability to feed, clothe, and in many cases, the power to heal.

Cannabis possesses a tremendous amount of wellness properties that can be used to treat a number of conditions, from chronic pain to insomnia.

Demand for medical cannabis research has existed for decades. Unfortunately, harmful prohibition policies in the United States and other areas has hindered research from filling that demand.

That’s not to say that there’s no cannabis research being conducted. As of this article, a search for ‘marijuana’ on PubMed.gov (US National Library of Medicine National Institutes of Health) returns over 31,000 results for peer-reviewed cannabis studies.

The current body of research is significant, however, it’s not enough. Researchers need to be able to study the cannabis plant without political hindrances and hurdles.

Australia’s Health Minister recently announced that a fund will be launched that will be dedicated to medical cannabis research. Per Reuters:

Australia will provide A$3 million ($2.03 million) for research on the use of cannabis to help cancer patients, its health minister said on Sunday, as the demand for medicinal cannabis products grows rapidly.

“There have only been a limited number of well-designed clinical studies on medicinal cannabis, and we need to increase the evidence base to support medical professionals,” a ministry statement cited him as saying.

Australia is home to a growing medical cannabis program that is experiencing strong growth with more and more patients being permitted to cultivate, acquire, and/or use medical cannabis.

The launch of the fund demonstrates that Australia is taking the issue of medical cannabis research seriously, provided that the studies involved are objective and free from bias.

Cannabis opponents in Australia and everywhere else around the world often cling to the false talking point that ‘there needs to be more cannabis research’ before laws can be reformed.

Those same opponents simultaneously do everything that they can to prevent research, which makes it clear that their motives are not based on compassion, but rather they are based on politics.

A sensible approach to cannabis policy involves scientific research and figuring out ways to get all of the best benefits that the cannabis plant can provide while also figuring out ways to mitigate any undesirable properties that may exist for certain patients and required treatment regimens.

Hopefully other countries follow Australia’s lead and embrace cannabis research instead of prohibiting or limiting it. Public health policies should be guided by science, and not the harmful political views of a handful of lawmakers.

Nevada Governor Forms Task Force After Report Of Failed Foreign Corruption Effort

A report came out this week involving a failed attempt by a group with Ukranian ties that were reportedly trying to obtain a Nevada cannabis business license via corrupt means. 

The report has resulted in Nevada’s Governor forming a task force to investigate any possible corruption in the state’s emerging legal cannabis industry.

A federal court indictment was filed on Friday in New York which charged four men with illegally funneling foreign money to political campaigns in the United States.

The indictment detailed how the men missed a September 2018 adult-use cannabis license application deadline and then reportedly organized an effort to try to convince Nevada’s Governor to change industry rules.

Contributions of $10,000 to the failed campaigns of Republican gubernatorial candidate Adam Laxalt and Republican attorney general candidate Wesley Duncan were determined to be part of the indictment once the indictment was crossreferenced with Nevada state political contribution records.

In addition to Laxalt and Duncan, the indictment also detailed troubling allegations involving one of the biggest cannabis opponents to ever serve in Congress, former Texas Republican Representative Pete Sessions. Pete Sessions was defeated in the 2018 election.

Nevada Governor Steve Sisolak issued the following press release on Friday after the indictment was filed:

Today, the Governor released the following statement regarding ongoing issues surrounding the legalized marijuana market as well as his immediate response in the form of a multi-state agency special task force:

The Governor is outraged by yesterday’s news that a foreign national attempted to influence Nevada’s elections through a million-dollar laundering scheme in order to gain a marijuana license and enter our legalized market.

Yesterday’s indictments and their connections to Nevada, in combination with ongoing issues in Nevada’s legalized marijuana industry – such as illegal sales to minors, serious allegations of manipulated lab results, and a licensing process mired in litigation – have led the Governor to expedite regulatory and enforcement measures. Many of these enhanced measures were originally intended to be implemented at the start of the Governor’s Cannabis Compliance Board, but in the interest of time and the public health and safety of Nevadans, the Governor has formed a multi-state agency special task force to root out potential corruption or criminal influences in Nevada’s marijuana marketplace, effective immediately. Any marijuana entity – licensed or unlicensed – that violates the law will see swift and severe criminal and regulatory action.

The Governor is disappointed in the lack of oversight and the inaction from the state over many years that led us to this critical juncture – including the apparent absence of a single criminal referral by the Marijuana Enforcement Division since the inception of licensed marijuana sales, medical or recreational, in Nevada. Governor Sisolak’s administration is taking immediate action in order to protect the health and safety of Nevadans, the jobs created by the industry, and the long-term sustainability of education funding generated from the legalized marketplace.

Brazilian Regulators To Vote On Medical Cannabis Proposals Tomorrow

Brazil is the largest nation in South America, as measured by population size, and the next closest country on the continent isn’t close. Brazil’s population of over 200 million people dwarfs the next closest country on the list, Colombia, which has a population of fewer than 50 million people.

A new, compassionate, and exciting industry being created out of thin air in Brazil would be a really big deal on a global scale because of how large the country is. Brazil is the fifth most populated country on earth.

That is what is happening right now, albeit slowly, right before our very eyes. The medical cannabis industry is coming to Brazil beyond imports of pharmaceutical-based cannabis medicines. 

Multiple proposals of regulatory models are currently being considered by Brazilian regulators, with a vote expected tomorrow. The vote was originally expected last week until a delay was announced leading up to the vote. Per Brazil’s National Health Surveillance Agency (Anvisa):

Some suggestions from the Agency’s directors on the texts of the Resolutions to be deliberated on Tuesday (8/10) on cultivation and registration of cannabis-based medicines need to be evaluated. Tema returns to the agenda of the Anvisa Collegiate Board at the next meeting, scheduled for October 15.

Initially, topics discussing criteria for cultivation and registration of plant-based drugs would be deliberated at the Board meeting on Tuesday (10/08).

However, some suggestions from the Agency’s directors were presented to the text. Prior to consideration by the Board of the Agency, the new considerations will be evaluated by the technical areas related to the topic, as well as by the Anvisa Attorney.

Brazil is currently a leading importer of pharmaceutical-based cannabis medicine. It’s far from being an optimal situation. Those types of products are extremely expensive compared to cannabis flower and other cannabis product options that are available in many legal cannabis markets.

Pharmaceutical-based cannabis products are not effective for a large number of suffering patients in Brazil. Those patients need legal access to other forms of cannabis that can be consumed via a wide array of consumption methods.

Domestically cultivated cannabis is what Brazilian lawmakers tasked the government with building a regulatory framework for, and once that becomes a reality, Brazil will likely become home to some of the cheapest medical cannabis options in the world.

It is no secret that cannabis grows better and easier in many parts of South America compared to the rest of the world, similar to other agricultural products. Brazil is no exception. The climate in many parts of Brazil is ideal for sungrown cannabis cultivation.

Not only could Brazil produce its own medical cannabis cheaper than current options for legal cannabis imports, it very well could end up cultivating so much cannabis that it creates the opportunity for Brazil to become a top cannabis exporter to countries around the globe.

Suffering patients in Brazil deserve better medical cannabis options, and individuals and entities that can do honest work and provide quality medicine to those patients should be allowed to legally do so. Hopefully this week’s vote is favorable and Brazil moves closer to implementing a legal, regulated medical cannabis industry.

Is A Regulated Adult-Use Cannabis Industry Coming To Mexico Soon?

Last year Mexico’s Supreme Court ruled that the country’s cannabis prohibition policy is unconstitutional. Mexico became, in a way, the third country to legalize cannabis, albeit via a court decision. Uruguay and Canada legalized cannabis for adult-use via the political process.

Mexico’s Supreme Court directed lawmakers to craft and approve cannabis legalization by the end of October 2019. We are, of course, in the middle of October 2019. It appears that lawmakers feel confident that they will meet the deadline, which was first reported by Marijuana Moment. Per the report:

The Senate leader of Mexico’s ruling party said that the lawmakers will vote on a bill to legalize marijuana for adult use by the end of the month.

There are numerous pieces of legalization legislation already on the table, but Sen. Ricardo Monreal of the MORENA party said his chamber is nearly done crafting a new reform bill that will be the product of weeks of public forums and open-session debates. Members of the other half of Mexico’s legislature, the Chamber of Deputies, will be invited to weigh in on the bill.

“We’re thinking that we’ll bring the law out, approve it, at the end of October,” Monreal said. “That’s the schedule we have.”

A number of pieces of legislation have been introduced and/or floated by various politicians in Mexico. However, from afar it appears that Senator Monreal’s bill has the greatest chance of actually becoming law.

As the push for legalization legislation moves along in Mexico, many entrepreneurs are wondering what it means in regards to the chances of a legal adult-use cannabis industry in Mexico becoming a reality. The ruling by Mexico’s Supreme Court did not call for a regulated cannabis industry.

Rather, it determined that personal possession, use, and cultivation of cannabis should be legal and the Court tasked lawmakers with making it officially happen. Mexico has been operating in a gray area while lawmakers work to pass the required legislation.

In the immediate future, assuming lawmakers get the job done, Mexico’s adult-use cannabis policy will be more like that of Washington D.C. and Vermont compared to Canada and states in the U.S. that have legal adult-use industries. Consumers will be able to gift cannabis, however, that’s the extent to which cannabis can legally change hands between consumers for adult-use purposes.

That will obviously limit the business opportunities for entrepreneurs that are looking to start-up in Mexico. Legislation creating a regulated adult-use industry will hopefully follow shortly after lawmakers in Mexico meet the Supreme Court’s mandate. Ultimately, only time will tell if that actually occurs, but luckily momentum for such a move appears to be building.

What’s Up With Local, Eurocentric Cannabis Production?

While the big Canadians are taking their beatings there is a new hum of something green and growing afoot in Europe. Namely, with all the buzz in the air about cannabiz business by the Canadians, the Americans, and just about everyone else, European farmers are not waiting things out.

The cannabis industry rules are starting to change and fairly drastically. Those on the ground in opening markets such as Malta, Spain, Portugal, Denmark, and Greece are doing the math. Traditional agricultural crops or medical cannabis, especially in an oil-based or distillate form. You don’t have to be Einstein to “do the math” and see the potential of cultivating cannabis.

Corporations saw the potential long ago, however, private farmers are eyeing the lucrative cannabis cultivation sector too. Those in the 10-30 million euro range are amply equipped to go to the bank for a loan at a standard European bank, to convert greenhouses already purposed to meet European food production guidelines.

That means that the party, as they say, is in fact just getting started. Calling all European family offices. 

A Turn In a Very Green Tide

For those who have not been watching, the world is changing fairly rapidly. Beyond the clean-up, let alone admission of the Great Garbage Patch, there are icebergs melting rapidly. All of those zombie apocalypse Netflix zingers have an awfully realistic view of what appears to be becoming reality rapidly.

You don’t have to be a 16-year-old girl to understand that the world is literally, melting.

This means a couple of things. For the cannabis industry, it means that local production of local medication is a political must that is showing up in a lot of international, if not transatlantic, discussions right now.

To people that honed their teeth on local, state, and even federal politics, the international perspective is equally bizarre. On the ground? It means that the local business communities left out of the conversation so far (from Germany and Spain to countries far from there) are finding a green vest cannabis voice that will not be stopped.

For all its hiccups and bumps, in other words, local European production is now in the room. And it isn’t goin’ back.

Be sure to attend the global 2020 International Cannabis Business Conferences in Barcelona, Berlin, Bern, San Francisco, and Vancouver, B.C.!